Lasa Supergenerics (LASA.NS) Stock Price

Lasa Supergenerics Price

CLOSED
4.22
​
Market closed

Revenue at Lasa Supergenerics has contracted by 20.5% per year over the past 9 years to 251.41 M INR. Earnings per share have grown at 52.7% per year over the last 4 years. For Lasa Supergenerics, the net margin of -135.6% is down versus -3.9% a few years ago. At today's price the dividend yield works out to roughly 5.92%. The payout ratio is around 4% of earnings.

Lasa Supergenerics stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lasa Supergenerics business model & stock analysis

Lasa Supergenerics Ltd manufactures veterinary preparations including API products such as Albendazole, Fenbendazole, Oxfendazole, Providone Iodine, Nitroxylene, Ricobendazole, Halquinol, and others. The company also produces animal feed ingredients like potassium iodide, cobalt sulfate, sodium selenate, ethylediamine dihydroiodide, and vanadyl sulfate, as well as reagents for therapeutic use including cetylpyridinium chloride, bismuth subsalicylate, and sodium selenite. Its manufacturing facility in Mahad and Chiplun, Maharashtra, supports the production of these specialized veterinary and pharmaceutical products. The company's primary customers are likely veterinary pharmaceutical manufacturers and animal health suppliers who require API products, feed additives, and therapeutic reagents. These segments include the veterinary pharmaceutical industry and animal feed production sectors, which rely on Lasa Supergenerics' specialized chemical formulations for their own product lines. The firm's focus on catalyst chemistry and anthelmintic/veterinary API products positions it within the niche market of veterinary pharmaceutical manufacturing. Lasa Supergenerics generates revenue through the sale of its API products, animal feed ingredients, and therapeutic reagents to veterinary and pharmaceutical companies. The company's product portfolio targets the veterinary pharmaceutical sector, where demand for anthelmintic and other API-based solutions is significant. By specializing in catalyst chemistry and producing high-demand veterinary API products, the company serves a specific market segment with tailored chemical solutions.

Frequently asked questions about Lasa Supergenerics

Converted at the current exchange rate, the Lasa Supergenerics share trades at 0.04 EUR (4.22 INR).

The revenue of Lasa Supergenerics is 251.41 M INR. This figure is based on current financial data and reflects the company's business performance.

The profit of Lasa Supergenerics is -340.90 M INR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Lasa Supergenerics is currently -0.62. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Lasa Supergenerics stock.

The price-to-sales ratio (P/S) of Lasa Supergenerics is currently 0.84. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Lasa Supergenerics stock.

The Eulerpool Quality Score for Lasa Supergenerics is 1/10.

The ISIN of Lasa Supergenerics is INE670X01014. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Lasa Supergenerics is LASA.NS. The ticker symbol is used to trade Lasa Supergenerics shares on the stock exchange.

Fair ValueTerminal
4.09 INR
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
2.82 M INR
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website lasalabs.com
Country
Currency
INR
Initial public offering
Sep 21, 2017
ISIN
INE670X01014
Cusip
Y5S74C106
Market capitalization
211.42 M INRMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2027
0.82
P/Ee 2028
0.65
P/S
P/Se
0.10
EV/EBIT
—
P/B Ratio
0.43
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-57.42 %
Dividend
Dividend yield
0.00 %
Est. Dividend Yield
5.92 %
Payout Ratio
4.46 %
Dividend growth Ø5Y
—
Dividend payments per year
1
Dividend paid since
0 years
Dividend not reduced since
0 years
Dividend increased since
0 years
Dividend withholding tax
20.00 %
Last updated Nov 16, 2026, 3:49 AM

Lasa Supergenerics Peer Group

Lasa Supergenerics FIGI

LASA:IN · BBG00GVNVNM0LASA:IB · BBG00GVNVNN9LASA:IS · BBG00GVNVNQ6